REVIEW Anacetrapib is a potent, selective, orally active, reversible rhCETP and mutant CETP(C13S) inhibitor which increases HDL-C and decreases LDL-C but does not increase aldosterone or blood pressure. It may reduce the development of atherosclerosis and it is being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.
REFERENCES
[1]
Gurfinkel, Ronen; Joy, Tisha R. Anacetrapib: hope for CETP inhibitors? Cardiovascular Therapeutics. (2011) 29(5): 327-339.
[2]
Aperis, Georgios; Paliouras, Christos; Tsampikaki, Eirini; Papakonstantinou, Nikolaos; Alivanis, Polichronis. Anacetrapib: a new weapon against dyslipidemia. Current Clinical Pharmacology. (2011) 6(4): 227-235.
[3]
Miyares, Marta A. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Annals of Pharmacotherapy. (2011) 45(1): 84-94.
[4]
Ali, Amjad; Napolitano, Joann M.; Deng, Qiaolin; Lu, Zhijian; Sinclair, Peter J.; Taylor, Gayle E.; Thompson, Christopher F.; Quraishi, Nazia; Smith, Cameron J.; Hunt, Julianne A.Preparation of cholesteryl ester transfer protein (CETP) inhibitors PCT Int. Appl. (2006), WO 2006014357 A1 20060209
All products are stocked and shipped from San Francisco Bay Area, California, USA.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
